Literature DB >> 29609040

Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia.

Dian Zhou1, Wei Chen2, Hai Cheng1, Jian-Lin Qiao1, Li-Li Zhu3, Zhen-Yu Li2, Kai-Lin Xu4.   

Abstract

Essential thrombocythemia (ET) is an uncommon chronic myeloproliferative disorder with no cure. Patients with ET are at risk of different complications, and currently there are no optimal prognostic standards to predict severe post-diagnosis complications such as thrombosis and hemorrhage. In this study, we retrospectively analyzed the full set of clinical data from 150 Chinese patients with ET enrolled from 2013 to 2016. We discovered that neutrophil-to-lymphocyte ratio (NLR), along with other known clinical parameters such as age, leukocyte count, incidence of thrombotic events is higher in patients with JAK2 V617F mutation. NLR is also higher in patients at high-risk stratification of thrombosis. Multivariate analysis showed that age (P = 0.001, 95% CI 1.023-1.089) and JAK2 V617F mutation (P = 0.003, 95% CI 1.837-21.035) were independent factors for thrombotic events, while age (P = 0.005, 95% CI 1.019-1.111) was the only predictive factor for hemorrhagic events at diagnosis. For future thrombotic events, multivariate analysis revealed NLR as the best predictive parameter (P < 0.001, 95% CI 1.173-1.486) when compared with other clinical parameters such as age (P = 0.037, 95% CI 1.004-1.126), thrombosis at diagnosis (P = 0.036, 95% CI 1.077-9.099) and WBC count (P = 0.047, 95% CI 1.001-1.109). Further ROC curve and Kaplan Meier analysis validated NLR as better prognostic marker for future thrombotic events and thrombosis-free survival. In summary, our data suggest that NLR parameter may possess great prognostic significance for future thrombosis in ET patients.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Essential thrombocythemia; Hemorrhage; Neutrophil-to-lymphocyte ratio; Thrombosis

Mesh:

Substances:

Year:  2018        PMID: 29609040     DOI: 10.1016/j.leukres.2018.03.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

1.  Genetic factors affecting thrombosis in patients with essential thrombocythemia by heparin treatment.

Authors:  Tomoyuki Kawada
Journal:  J Thromb Thrombolysis       Date:  2019-10       Impact factor: 2.300

Review 2.  Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.

Authors:  Ivan Krecak; Marko Lucijanic; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2022-08-06       Impact factor: 4.213

3.  Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

Authors:  Tomoki Ito; Yoshinori Hashimoto; Yasuhiro Tanaka; Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Akiko Hashimoto; Toshinori Kondo; Hiromi Omura; Isaku Shinzato; Takayuki Tanaka; Shosaku Nomura
Journal:  Eur J Haematol       Date:  2019-06-17       Impact factor: 2.997

Review 4.  The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies - A Narrative Review.

Authors:  Paulina Stefaniuk; Agnieszka Szymczyk; Monika Podhorecka
Journal:  Cancer Manag Res       Date:  2020-04-29       Impact factor: 3.989

5.  Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera.

Authors:  Alessandra Carobbio; Alessandro Maria Vannucchi; Valerio De Stefano; Arianna Masciulli; Paola Guglielmelli; Giuseppe Gaetano Loscocco; Francesco Ramundo; Elena Rossi; Yogendra Kanthi; Ayalew Tefferi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2022-02-10       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.